Covidien has finalized a deal to acquire Barrx Medical for $325 million in cash, according to a Wall Street Journal report.
The purchase brings Covidien into the gastroenterology field. Barrx will be operated as a standalone division of Covidien and staffed by current Barrx employees.
The company's offerings include the Halo system, a radiofrequency ablation device to treat Barrett's esophagus by using radiofrequency energy to remove a thin layer of tissue off the inner esophageal lining so healthy tissue can grow.
Related Articles on Gastroenterology:
Study: Laparoscopic Surgery May be Safer Than Open Bariatric Surgery
Median Survival Time for Colon Cancer Increases 17-Fold
IBD Patients Face Higher Risk of Skin Cancer
The purchase brings Covidien into the gastroenterology field. Barrx will be operated as a standalone division of Covidien and staffed by current Barrx employees.
The company's offerings include the Halo system, a radiofrequency ablation device to treat Barrett's esophagus by using radiofrequency energy to remove a thin layer of tissue off the inner esophageal lining so healthy tissue can grow.
Related Articles on Gastroenterology:
Study: Laparoscopic Surgery May be Safer Than Open Bariatric Surgery
Median Survival Time for Colon Cancer Increases 17-Fold
IBD Patients Face Higher Risk of Skin Cancer